Cytomx’s expanded readout supports late-stage testing of masked EpCAM ADC 

New data from Cytomx in an expanded colorectal cancer cohort remain encouraging, and mark the second clinical update in recent weeks to suggest masked therapeutics are improving therapeutic index.

Cytomx Therapeutics Inc. (NASDAQ:CTMX) announced Monday that 32% of patients with advanced colorectal cancer who received a 10 mg/kg dose of Varsetatug masetecan (Varseta-M) in a dose expansion cohort of the Phase I CTMX-2051-101 study achieved an objective response. Progression-free survival was 7.1 months...